Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 03/13/17 → 01/20/18 |
Funding
- Eli Lilly and Company: $13,530.00
Randomized, Double-Blind, Phase 2 Study of Ramucirunab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
- Keresztes, Roger (CoPI)
- Choi, Minsig (PI)
- Zhang, Yue (CoPI)
Project: Research